We are live on ! Find out more
MG

Michael Gelband ExodusPoint Capital Management

AUM $15.5B
1-Year Est. Return 38.81%
 

Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.

This Fund
S&P 500
This Quarter Est. Return
+11.09%
1 Year Est. Return
+38.81%
3 Year Est. Return
+110.53%
5 Year Est. Return
+124.16%
10 Year Est. Return
–
AUM
$11.4B
AUM Growth
+$1.29B
Cap. Flow
+$528M
Cap. Flow %
4.63%
Top 10 Hldgs %
25.25%
Holding
2,093
New
704
Increased
330
Reduced
366
Closed
687

Top Buys

Rank Stock Value
1
PARA
Paramount Global Class B
PARA
+$75M
2
CVX icon
Chevron
CVX
+$59.9M
3
GEHC icon
GE HealthCare
GEHC
+$57.5M
4
APP icon
Applovin
APP
+$54.7M
5
OKLO
Oklo
OKLO
+$52.8M

Top Sells

Rank Stock Value
1
XEL icon
Xcel Energy
XEL
+$137M
2
META icon
Meta Platforms (Facebook)
META
+$61.8M
3
BDX icon
Becton Dickinson
BDX
+$59.9M
4
CRWV
CoreWeave
CRWV
+$57.1M
5
AAPL icon
Apple
AAPL
+$50.2M

Sector Composition

Rank Sector Weight
1 Healthcare 11.73%
2 Financials 9.81%
3 Utilities 8.63%
4 Technology 7.6%
5 Industrials 7.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BF.A icon
1401
Brown-Forman Class A
BF.A
$13.3B
$6K ﹤0.01%
+202
New +$6.48K
APLT
1402
DELISTED
Applied Therapeutics
APLT
$3K ﹤0.01%
+10,457
New +$4.05K
LNZA icon
1403
LanzaTech
LNZA
$81.8M
$3K ﹤0.01%
119
-94
-44% -$2.31K
MRSN
1404
DELISTED
Mersana Therapeutics
MRSN
$3K ﹤0.01%
+457
New +$4.02K
LNAI
1405
Lunai Bioworks
LNAI
$9.77M
$3K ﹤0.01%
+151
New +$4.22K
GEF.B icon
1406
Greif Class B
GEF.B
$4.22B
$1K ﹤0.01%
+15
New +$910
A icon
1407
Agilent Technologies
A
$44.9B
– –
-12,101
Closed -$1.42M
AAL icon
1408
American Airlines Group
AAL
$9.15B
– –
-571,056
Closed -$6.03M
AAON icon
1409
Aaon
AAON
$6.55B
– –
-9,595
Closed -$750K
AAPL icon
1410
Apple
AAPL
$4.51T
– –
-225,897
Closed -$50.2M
ABBV icon
1411
AbbVie
ABBV
$468B
– –
-51,628
Closed -$10.8M
ABEO icon
1412
Abeona Therapeutics
ABEO
$348M
– –
-24,409
Closed -$116K
ABG icon
1413
Asbury Automotive
ABG
$3.86B
– –
-6,947
Closed -$1.53M
ACA icon
1414
Arcosa
ACA
$7.12B
– –
-13,013
Closed -$1M
ACAD icon
1415
Acadia Pharmaceuticals
ACAD
$5.08B
– –
-37,491
Closed -$623K
ACCO icon
1416
Acco Brands
ACCO
$391M
– –
-33,830
Closed -$142K
ACRS icon
1417
Aclaris Therapeutics
ACRS
$944M
– –
-59,865
Closed -$92K
ADP icon
1418
Automatic Data Processing
ADP
$112B
– –
-22,806
Closed -$6.97M
ADSK icon
1419
Autodesk
ADSK
$53.6B
– –
-44,221
Closed -$11.6M
ADTN icon
1420
Adtran
ADTN
$633M
– –
-200,014
Closed -$1.74M
ADUS icon
1421
Addus HomeCare
ADUS
$2.26B
– –
-5,586
Closed -$552K
AESI icon
1422
Atlas Energy Solutions
AESI
$1.57B
– –
-141,399
Closed -$2.52M
AGIO icon
1423
Agios Pharmaceuticals
AGIO
$1.98B
– –
-10,553
Closed -$309K
AHCO icon
1424
AdaptHealth
AHCO
$751M
– –
-56,629
Closed -$614K
AIG icon
1425
American International
AIG
$39.8B
– –
-43,564
Closed -$3.79M
55 56
57
58 59

Similar funds

FGP
Freestone Grove Partners San Francisco, California $15.6B AUM 27.39% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
AA
Acorns Advisers Irvine, California $15.3B AUM 18.32% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $15.8B AUM 1.29% 1-Year Est. Return
NMIFOAC
National Mutual Insurance Federation of Agricultural Cooperatives Tokyo, Japan, Japan $15.3B AUM 24.71% 1-Year Est. Return

Michael Gelband's Q2 2025 Portfolio in Review

As of Q2 2025, Michael Gelband held 2,093 positions worth $11.4B, up 13% from $10.1B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Michael Gelband deployed $528M of net new capital in Q2 2025, opening 704 new positions and adding to 330 existing holdings. Its largest new stake was Chevron: 424,949 shares worth $60.8M.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 13% a quarter earlier, followed by Financials and Utilities.

On the sell side, the largest reduction was Xcel Energy, an estimated $137M trimmed.

  • Michael Gelband's largest Q2 2025 buy was Chevron: 424,949 shares worth $60.8M.
  • Michael Gelband added most to Paramount Global Class B in Q2 2025, an estimated $75M increase.
  • Michael Gelband's biggest Q2 2025 reduction was Xcel Energy, cutting an estimated $137M.
  • Michael Gelband fully exited Meta Platforms (Facebook) in Q2 2025, selling an estimated $61.8M.
  • Michael Gelband's ten largest holdings make up 25% of its $11.4B portfolio in Q2 2025.
  • Michael Gelband opened 704 new positions and closed 687 in Q2 2025.
  • Michael Gelband's portfolio value rose 13% quarter-over-quarter to $11.4B.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.